Does the media prefer ATAI or RYTM?

In the previous week, Atai Beckley had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Rhythm Pharmaceuticals. Atai Beckley's average media sentiment score of 0.78 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or ATAI?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 5 mentions for Atai Beckley. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Atai Beckley's score of 0.78 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TGTX or ATAI?

TG Therapeutics has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $700.35M 8.87 $447.18M $2.86 14.18 Atai Beckley $4.09M 405.08 -$660.05M -$2.23 N/A

Does the media favor TGTX or ATAI?

In the previous week, TG Therapeutics had 8 more articles in the media than Atai Beckley. MarketBeat recorded 13 mentions for TG Therapeutics and 5 mentions for Atai Beckley. TG Therapeutics' average media sentiment score of 0.82 beat Atai Beckley's score of 0.78 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTA or ATAI?

In the previous week, Atai Beckley had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 1 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Atai Beckley's score of 0.78 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATAI or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -19,019.44% -89.79% -63.58% Scholar Rock N/A -163.52% -96.67%

Atai Beckley (ATAI) Competitors

$4.50 -0.03 (-0.66%)

Closing price 06/4/2026 04:00 PM Eastern

Extended Trading

$4.54 +0.04 (+0.98%)

As of 05:32 AM Eastern

Compare

ATAI vs. RYTM, MIRM, TGTX, CNTA, and SRRK

Should you buy Atai Beckley stock or one of its competitors? MarketBeat compares Atai Beckley with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atai Beckley include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), Centessa Pharmaceuticals (CNTA), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Atai Beckley (NASDAQ:ATAI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

28.4% of Atai Beckley shares are held by institutional investors. 26.8% of Atai Beckley shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Atai Beckley has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

Atai Beckley presently has a consensus price target of $16.00, suggesting a potential upside of 255.56%. Rhythm Pharmaceuticals has a consensus price target of $131.81, suggesting a potential upside of 50.45%. Given Atai Beckley's stronger consensus rating and higher possible upside, equities research analysts plainly believe Atai Beckley is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has higher revenue and earnings than Atai Beckley. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	405.08	-$660.05M	-$2.23	N/A
Rhythm Pharmaceuticals	$217.17M	27.65	-$196.54M	-$3.13	N/A

In the previous week, Atai Beckley had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Rhythm Pharmaceuticals. Atai Beckley's average media sentiment score of 0.78 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atai Beckley beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Mirum Pharmaceuticals presently has a consensus price target of $137.64, suggesting a potential upside of 48.82%. Atai Beckley has a consensus price target of $16.00, suggesting a potential upside of 255.56%. Given Atai Beckley's higher possible upside, analysts clearly believe Atai Beckley is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Mirum Pharmaceuticals has a net margin of -140.24% compared to Atai Beckley's net margin of -19,019.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

28.4% of Atai Beckley shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 26.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mirum Pharmaceuticals has higher revenue and earnings than Atai Beckley. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	10.82	-$23.36M	-$13.61	N/A
Atai Beckley	$4.09M	405.08	-$660.05M	-$2.23	N/A

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Atai Beckley. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 5 mentions for Atai Beckley. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat Atai Beckley's score of 0.78 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Atai Beckley on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

TG Therapeutics currently has a consensus target price of $52.50, suggesting a potential upside of 29.44%. Atai Beckley has a consensus target price of $16.00, suggesting a potential upside of 255.56%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts plainly believe Atai Beckley is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 26.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$700.35M	8.87	$447.18M	$2.86	14.18
Atai Beckley	$4.09M	405.08	-$660.05M	-$2.23	N/A

TG Therapeutics has a net margin of 65.95% compared to Atai Beckley's net margin of -19,019.44%. TG Therapeutics' return on equity of 88.73% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

In the previous week, TG Therapeutics had 8 more articles in the media than Atai Beckley. MarketBeat recorded 13 mentions for TG Therapeutics and 5 mentions for Atai Beckley. TG Therapeutics' average media sentiment score of 0.82 beat Atai Beckley's score of 0.78 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Centessa Pharmaceuticals' return on equity of -60.37% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Centessa Pharmaceuticals has higher revenue and earnings than Atai Beckley. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	395.96	-$197.53M	-$1.79	N/A
Atai Beckley	$4.09M	405.08	-$660.05M	-$2.23	N/A

Centessa Pharmaceuticals currently has a consensus price target of $41.33, suggesting a potential upside of 3.85%. Atai Beckley has a consensus price target of $16.00, suggesting a potential upside of 255.56%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Atai Beckley had 4 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 5 mentions for Atai Beckley and 1 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat Atai Beckley's score of 0.78 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atai Beckley beats Centessa Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Scholar Rock?

Atai Beckley (NASDAQ:ATAI) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

In the previous week, Atai Beckley had 5 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Atai Beckley and 0 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Atai Beckley's score of 0.78 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Positive
Scholar Rock	Very Positive

Atai Beckley has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Atai Beckley presently has a consensus price target of $16.00, indicating a potential upside of 255.56%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 23.54%. Given Atai Beckley's higher possible upside, analysts clearly believe Atai Beckley is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 26.8% of Atai Beckley shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scholar Rock has lower revenue, but higher earnings than Atai Beckley. Scholar Rock is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	405.08	-$660.05M	-$2.23	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Scholar Rock has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Atai Beckley beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$5.52B	$6.30B	$12.43B
Dividend Yield	N/A	1.59%	2.69%	5.33%
P/E Ratio	-2.02	33.09	23.78	24.34
Price / Sales	405.08	25.18	532.69	115.17
Price / Cash	N/A	15.72	41.39	55.53
Price / Book	6.52	3.08	10.04	6.72
Net Income	-$660.05M	$218.81M	$3.56B	$337.03M
7 Day Performance	-0.66%	-1.66%	-0.99%	-0.13%
1 Month Performance	12.50%	-0.63%	2.25%	3.76%
1 Year Performance	81.45%	9.80%	29.11%	34.36%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	3.1296 of 5 stars	$4.50 -0.7%	$16.00 +255.6%	+82.2%	$1.67B	$4.09M	N/A	80	News Coverage
RYTM Rhythm Pharmaceuticals	2.5631 of 5 stars	$87.84 flat	$131.81 +50.1%	+36.1%	$6.02B	$189.76M	N/A	140	Analyst Forecast
MIRM Mirum Pharmaceuticals	3.6022 of 5 stars	$98.62 flat	$137.08 +39.0%	+107.3%	$6.01B	$521.31M	N/A	140	Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.8151 of 5 stars	$38.87 flat	$52.50 +35.1%	+9.5%	$5.95B	$616.29M	13.59	290
CNTA Centessa Pharmaceuticals	2.1662 of 5 stars	$39.75 flat	$40.70 +2.4%	+217.6%	$5.93B	$15M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Summary

How does Atai Beckley compare to Mirum Pharmaceuticals?

Summary

How does Atai Beckley compare to TG Therapeutics?

Summary

How does Atai Beckley compare to Centessa Pharmaceuticals?

Summary

How does Atai Beckley compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Do institutionals & insiders hold more shares of ATAI or RYTM?

Is ATAI or RYTM more profitable?

Which has more risk & volatility, ATAI or RYTM?

Do analysts rate ATAI or RYTM?

Which has higher earnings & valuation, ATAI or RYTM?

Does the media prefer ATAI or RYTM?

Summary

How does Atai Beckley compare to Mirum Pharmaceuticals?

Do analysts rate MIRM or ATAI?

Is MIRM or ATAI more profitable?

Do insiders & institutionals hold more shares of MIRM or ATAI?

Which has higher earnings & valuation, MIRM or ATAI?

Does the media favor MIRM or ATAI?

Which has more risk & volatility, MIRM or ATAI?

Summary

How does Atai Beckley compare to TG Therapeutics?

Do analysts rate TGTX or ATAI?

Do institutionals and insiders hold more shares of TGTX or ATAI?

Which has more volatility & risk, TGTX or ATAI?

Which has preferable valuation & earnings, TGTX or ATAI?

Is TGTX or ATAI more profitable?

Does the media favor TGTX or ATAI?

Summary

How does Atai Beckley compare to Centessa Pharmaceuticals?

Which has more volatility & risk, CNTA or ATAI?

Do institutionals & insiders have more ownership in CNTA or ATAI?

Is CNTA or ATAI more profitable?

Which has preferable earnings & valuation, CNTA or ATAI?

Do analysts prefer CNTA or ATAI?

Does the media favor CNTA or ATAI?

Summary

How does Atai Beckley compare to Scholar Rock?

Does the media refer more to ATAI or SRRK?

Which has more risk and volatility, ATAI or SRRK?

Do analysts recommend ATAI or SRRK?

Do institutionals & insiders believe in ATAI or SRRK?

Which has preferable valuation and earnings, ATAI or SRRK?

Is ATAI or SRRK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools